CLAIMS

1. Use of a peroral composition comprising procyanidins in the manufacture of a medicament for the treatment of endothelial inflammation and/or endothelial systemic dysfunction in a symptomatic post-COVID-19 subject, wherein the endothelial inflammation and/or endothelial dysfunction is triggered by Corona virus disease 2019 (COVID-19) induced by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) infection.

2. The use according to claim 1, wherein the peroral composition is a source of constituents selected from the group consisting of δ-(3,4-dihydroxyphenyl)-γ-valerolactone, δ-(3-Methoxy-4-hydroxy-phenyl)-γ-valerolactone, catechin, epicatechin, ferulic acid, gallic acid, 4-hydroxybenzoic acid, caffeic acid, protocatechuic acid, taxifolin and mixtures thereof.

3. The use according to claim 1 or 2, wherein the peroral composition comprises from 20 % to 95 % w/w of the procyanidins.

4. The use according to claim 3, wherein the peroral composition comprises from 65 % to 75 % w/w of the procyanidins.

5. The use according to any one of claims 1 to 4, wherein the procyanidins originate from a plant extract selected from the group consisting of extracts of pine bark, grape seed, apples, cocoa, peanut skin, cranberry and combinations thereof.

6. The use according to claim 5, wherein the plant extract is an extract of *Pinus pinaster* bark.

7. The use according to claim 6, wherein the extract of *Pinus pinaster* bark is Pycnogenol®.

8. The use according to any one of claims 1 to 7, wherein the medicament is to be orally administered at a daily dosage from 25 mg to 300 mg.

9. The use according to any one of claims 1 to 8, wherein the endothelial systemic dysfunction is selected from the group consisting of endothelial blood flow and microcirculation dysfunction, and endothelial coagulation dysfunction.

10. The use according to claim 9, wherein the endothelial blood flow and microcirculation dysfunction is selected from the group consisting of kidney dysfunction, lung dysfunction, liver dysfunction, brain cognitive dysfunction, endothelial dysfunction-related hypertension, and endothelial dysfunction-related altered blood velocity.

11. The use according to claim 9, wherein the endothelial coagulation dysfunction is thrombosis or platelet aggregation.

12. The use according to any one of claims 1 to 11, wherein the endothelial inflammation is selected from the group consisting of endotheliitis, myocarditis, and vasculitis.

13. The use according to claim 12, wherein the vasculitis is a Kawasaki-like disease.

14. The use according to claim 12, wherein the endotheliitis is severe endotheliitis.